Smith Caleb, Hendrickson Andrea Wahner, Grudem Megan, Klampe Carolyn, Deering Erin, Jatoi Aminah
Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Am J Hosp Palliat Care. 2020 Mar;37(3):235-238. doi: 10.1177/1049909119864083. Epub 2019 Jul 17.
Seventy percentage of patients who receive paclitaxel have diffuse, refractory myalgias, and arthralgias. Based on anecdotal reports, this study explored whether loratadine, an antihistamine, palliates these symptoms.
The medical records of postoperative ovarian and patients with endometrial cancer were studied, as these patients are routinely prescribed paclitaxel. Records were screened for patients who received paclitaxel and loratadine concurrently.
Forty patients are the focus of this report. Eight had paclitaxel-induced myalgias and arthralgias and then took loratadine; of these, 6 (75%; 95% confidence interval: 35%, 97%) manifested evidence of symptom improvement: "She did experience some migrating generalized body aches and pains…but this has resolved." Of those already receiving loratadine but with no myalgias and arthralgias, only 11 of 32, or 34% (95% confidence interval: 19%, 53%), developed myalgias and arthralgias (in contrast to the previously reported symptom rate of 70%). No adverse events were clearly attributed to loratadine.
These preliminary data support further study of loratadine for paclitaxel-induced myalgias and arthralgias.
接受紫杉醇治疗的患者中有70%出现弥漫性、难治性肌痛和关节痛。基于轶事报道，本研究探讨了抗组胺药氯雷他定是否能缓解这些症状。
对卵巢癌和子宫内膜癌术后患者的病历进行研究，因为这些患者通常会被常规开用紫杉醇。筛选同时接受紫杉醇和氯雷他定治疗的患者的病历。
本报告聚焦于40名患者。其中8名患者出现紫杉醇诱导的肌痛和关节痛，随后服用氯雷他定；其中6名（75%；95%置信区间：35%，97%）症状有改善迹象：“她确实经历了一些游走性全身酸痛……但这已经缓解了。”在已服用氯雷他定但无肌痛和关节痛的患者中，32名患者中只有11名，即34%（95%置信区间：19%，53%）出现了肌痛和关节痛（与之前报道的70%的症状发生率形成对比）。没有明确的不良事件归因于氯雷他定。
这些初步数据支持进一步研究氯雷他定治疗紫杉醇诱导的肌痛和关节痛的效果。
